LadRx Corp
LADX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LADX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LADX
LadRx Corp (LADX) is a biopharmaceutical company focused on developing product candidates based on its LADR™ technology, with no approved products and a history of operating losses.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
LadRx Corp (LADX) is a biopharmaceutical company focused on developing product candidates based on its LADR™ technology, with no approved products and a history of operating losses.
- LadRx has no source of significant recurring revenue and relies on capital raising to sustain operations [sec · filed 2019-03-29].
- As of 2025-03-31, the company reported cash & equivalents of $0.2M, net income of -$0.7M, and shareholders' equity of -$1.4M [sec].
- The company has not obtained regulatory approval for any product candidate [sec · filed 2019-03-29].
- Research and development expenses were $0.4 million in 2018 and $19.8 million in 2017 [sec · filed 2019-03-29].
- LadRx has operated at a loss due to ongoing R&D and G&A expenditures, and expects to continue operating at a loss for the foreseeable future [sec · filed 2019-03-29].
What works
- The company has a proprietary LADR™ technology platform that it believes has revenue potential [sec · filed 2019-03-29].
- Management has historically projected that resources would be sufficient to fund operations for the foreseeable future, based on projected expenditures [sec · filed 2019-03-29].
What to weigh
- The company has no approved products and no significant recurring revenue, making it dependent on capital raising [sec · filed 2019-03-29].
- As of 2025-03-31, the company had negative shareholders' equity of -$1.4M and only $0.2M in cash [sec].
- Clinical development is lengthy, expensive, and subject to numerous delays and uncertainties [sec · filed 2019-03-29].
- The company may need to increase authorized shares to raise additional capital, which would dilute existing stockholders [sec · filed 2019-03-29].
From the filings
Quoted directly from source documents.
The company has no source of significant recurring revenue and must rely on capital raising.
“Because we have no source of significant recurring revenue, we must depend on capital raising to sustain our operations, and our ability to raise capital may be severely limited.”
SEC filings · March 29, 2019
The company has not obtained regulatory approval for any product candidate.
“We have not obtained regulatory approval for any product candidate.”
SEC filings · March 29, 2019
The company has operated at a loss and expects to continue doing so.
“We have operated at a loss due to our ongoing expenditures for research and development of our product candidates and for general and administrative purposes, and lack of s”
SEC filings · March 29, 2019
Research and development expenses were $0.4 million in 2018.
“development activities related to continuing operations were $0.4 million in 2018”
SEC filings · March 29, 2019
Risks & what to watch (4)›
Key risks
- No approved products — The company has not obtained regulatory approval for any product candidate, and clinical development is lengthy and uncertain [sec · filed 2019-03-29].
- Negative equity and low cash — As of 2025-03-31, shareholders' equity was -$1.4M and cash was $0.2M, indicating severe financial strain [sec].
- Dependence on capital raising — The company has no significant recurring revenue and must raise capital to continue operations, which may be limited [sec · filed 2019-03-29].
- Potential shareholder dilution — The company may need to increase authorized shares to raise capital, diluting existing stockholders [sec · filed 2019-03-29].
What to watch
- Ability to raise additional capital given low cash and negative equity [sec].
- Progress of any clinical trials or regulatory filings for product candidates [sec · filed 2019-03-29].
- Any strategic alternatives or partnerships that may be pursued [sec · filed 2019-03-29].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run LadRx Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LadRx Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.2 months
OCF -$553K · Net income -$719K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 21, 2026- % of float
- 0.8%
- Days to cover
- 1.0
- Shares short
- 2,517
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LADX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LadRx Corp?
LadRx Corp (LADX) is a biopharmaceutical company focused on developing product candidates based on its LADR™ technology, with no approved products and a history of operating losses.
Who is the CEO of LadRx Corp?
Stephen Snowdy is the chief executive officer of LadRx Corp (LADX).
Where is LadRx Corp headquartered?
LadRx Corp (LADX) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does LadRx Corp focus on?
LadRx Corp develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.